The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•17 March 2026•

1 min read

Virbac Reports 7.9% Organic Revenue Growth in 2025 Despite Operational Hurdles

A man in a suit over a stock chart with 'Mondelez International' text, surrounded by chocolate, cocoa beans, factories, and shops.

Key Facts

1Virbac achieved organic revenue growth of 7.9% at constant exchange rates and scope (CERS).

2The adjusted EBIT margin reached 16.3% despite production shutdowns and inventory write-offs.

Version History

1 additional source confirmed this story

Animal health specialist Virbac released its annual financial results for 2025, demonstrating resilient performance amid operational challenges. The company achieved organic revenue growth of 7.9% at constant exchange rates and scope (CERS). The adjusted EBIT margin reached 16.3%, a solid figure considering temporary production shutdowns and inventory write-offs. Growth was primarily driven by a 5% contribution from volume and product mix, supplemented by a 3% increase from price adjustments. Strong momentum across key product categories and geographic regions helped offset the impact of one-off operational setbacks. These results highlight Virbac's robust underlying business performance and its ability to maintain healthy margins.